Loading clinical trials...
Loading clinical trials...
Phase II Study on Acalabrutinib and Anti-CD20 Antibody in Patients With Predominantly Demyelinating Neuropathy With or Without Anti-MAG
Conditions
Interventions
Acalabrutinib
Rituximab
Locations
2
United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Start Date
November 16, 2021
Primary Completion Date
December 1, 2026
Completion Date
October 1, 2028
Last Updated
December 5, 2025
NCT01804686
NCT02269592
NCT05602363
NCT04893564
NCT06912646
NCT06340737
Lead Sponsor
Shayna Sarosiek, MD
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions